Harmony Biosciences Holdings (HRMY) Amortizatization of Intangibles (2019 - 2026)
Harmony Biosciences Holdings recorded quarterly Amortizatization of Intangibles of $220000.0 in Q1 2026, down 21.71% quarter-over-quarter from $281000.0 in Q4 2025, and down 96.31% year-over-year from $6.0 million in Q1 2025.
Harmony Biosciences Holdings' Amortizatization of Intangibles history runs 8 years deep, the most recent figure standing at $220000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 96.31% year-over-year to $220000.0; the TTM figure through Mar 2026 stood at $12.4 million (down 68.91% YoY), while the FY2025 annual figure was $1.5 million, down 93.62% from the prior year.
- Amortizatization of Intangibles came in at $220000.0 for Q1 2026 at Harmony Biosciences Holdings, down from $281000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $22.1 million in Q4 2024 to a low of -$15.2 million in Q4 2023.
- A 5-year average of $4.6 million and a median of $6.0 million in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles surged 1825.0% in 2022 and plunged 354.47% in 2023, its largest moves.
- Harmony Biosciences Holdings' Amortizatization of Intangibles stood at $6.0 million in 2022, then slumped by 354.47% to -$15.2 million in 2023, then soared by 245.53% to $22.1 million in 2024, then plunged by 98.73% to $281000.0 in 2025, then dropped by 21.71% to $220000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $220000.0, $281000.0, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | 220,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 220,000.00 |
| Mar 31, 2026 | 220,000.00 |
| Dec 31, 2025 | 281,000.00 |
| Dec 31, 2025 | 281,000.00 |
| Sep 30, 2025 | 5.96 Mn |
| Sep 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 5.96 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Dec 31, 2024 | 22.08 Mn |
| Dec 31, 2024 | 22.08 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 5.96 Mn |
| Mar 31, 2024 | 5.96 Mn |
| Mar 31, 2024 | 5.96 Mn |
| Dec 31, 2023 | -15.17 Mn |
| Dec 31, 2023 | -15.17 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 636,000.00 |
| Mar 31, 2023 | 636,000.00 |
| Dec 31, 2022 | 5.96 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Sep 30, 2022 | 5.96 Mn |
| Sep 30, 2022 | 5.96 Mn |
| Jun 30, 2022 | 5.96 Mn |
| Jun 30, 2022 | 5.96 Mn |
| Mar 31, 2022 | 5.08 Mn |
| Mar 31, 2022 | 5.08 Mn |
| Dec 31, 2021 | 4.64 Mn |
| Dec 31, 2021 | 4.64 Mn |
| Sep 30, 2021 | 4.57 Mn |
| Sep 30, 2021 | 4.57 Mn |
| Jun 30, 2021 | 4.63 Mn |
| Jun 30, 2021 | 4.63 Mn |
| Mar 31, 2021 | 264,000.00 |
| Mar 31, 2021 | 264,000.00 |
| Dec 31, 2020 | 4.28 Mn |
| Dec 31, 2020 | 4.28 Mn |
| Sep 30, 2020 | 1.87 Mn |
| Sep 30, 2020 | 1.87 Mn |
| Jun 30, 2020 | 1.91 Mn |
| Jun 30, 2020 | 1.91 Mn |
| Mar 31, 2020 | 1.79 Mn |
| Mar 31, 2020 | 1.79 Mn |
| Dec 31, 2019 | 1.85 Mn |
| Dec 31, 2019 | 1.85 Mn |